FY ended Dec 31, 2025 · figures in Php except per-share rows
| Item | Current | Previous |
|---|---|---|
| Current assets | 5,623,063,831 | 5,318,058,680 |
| Total assets | 11,144,610,477 | 10,949,904,739 |
| Current liabilities | 3,832,620,971 | 3,909,260,781 |
| Total liabilities | 5,076,455,877 | 5,067,004,801 |
| Retained earnings/(deficit) | 1,906,159,188 | 1,723,917,468 |
| Stockholders' equity | 6,068,154,600 | 5,882,899,938 |
| Stockholders' equity (parent) | 5,933,653,304 | 5,806,576,087 |
| Book value per share | ₱1.48 | ₱1.43 |
| Item | Current | Previous |
|---|---|---|
| Gross revenue | 6,868,245,695(+18.5%) | 5,796,044,756 |
| Gross expense | 5,968,595,962 | 5,127,015,104 |
| Income/(loss) before tax | 637,096,263 | 437,459,230 |
| Net income/(loss) after tax | 470,295,675(+39.3%) | 337,677,687 |
| Net income/(loss), parent | 414,927,055 | 334,861,399 |
| EPS (basic) | ₱0.10 | ₱0.08 |
| EPS (diluted) | ₱0.10 | ₱0.08 |
Euro-Med Laboratories Philippines, Inc. (EURO) was incorporated and registered with the Securities and Exchange Commission on January 29, 1988. Upon receipt of the licenses and product registration approvals from the Food and Drug Administration Philippines, EURO began commercial production in 1991.
EURO is engaged in the manufacture of pharmaceutical products such as large and small volume parenteral and other solutions. The Company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation and dialysis. EURO is likewise engaged in the toll manufacturing of pharmaceutical products in liquid form.
The Company's subsidiaries are Hemotek Renal Center, Inc., which is engaged as a dialysis center; and CafeFrance Corp., which is engaged to operate restaurants, bakeries, food services, catering, food production, and other related services.
Euro-Med Laboratories Phil., Inc. (PSE: EURO) last traded at ₱1.14, up 0.00% on the day, as of Oct 26, 2026. Prices on this page are delayed or end-of-day, not real time.
Euro-Med Laboratories Phil., Inc. trades on the Philippine Stock Exchange under the ticker symbol EURO.
EURO is listed in the Industrial sector of the Philippine Stock Exchange, where it ranks #41 of 74 by market capitalization. Across the whole exchange it is #140 of 282, at ₱4.7B.
EURO trades at a price-to-earnings ratio of 11.4 and a price-to-book of 0.77, based on basic earnings per share from its latest annual filing (fiscal year ended Dec 31, 2025). Annual figures can be up to a year old, so this is not a trailing-twelve-month multiple.
PSEye doesn't label any stock overvalued or undervalued. EURO currently trades at a P/E of 11.4 and a P/B of 0.77, but whether that's cheap or expensive depends on the sector, growth prospects, and what comparable companies trade at, none of which a ratio alone can tell you. For comparison, Industrial peers with a computable ratio trade at a sector median P/E of 7.6 and a sector median P/B of 0.99 (49 peers). The Sector peers panel above lists 10 similarly-sized Industrial companies to compare against directly.
PSEye has no cash dividend on record for EURO in roughly the last two years. That is a statement about the corporate actions published on PSE Edge over that window, not a guarantee the company has never paid or will not pay one.
In its latest annual filing (fiscal year ended Dec 31, 2025), EURO's revenue grew 18.5% and net income grew 39.3% versus the prior fiscal year. That's one year-over-year comparison, not a multi-year trend, so check the Balance sheet & income statement panel above for the full figures before drawing a conclusion.
PSEye doesn't rate stocks as good or bad buys. What this page can tell you is factual: where EURO ranks by market cap (#140 of 282 on the exchange), its price history, valuation ratios, dividend record and recent company disclosures, all shown above. Whether that adds up to a good stock depends on your own criteria, and is worth researching beyond any single page, including this one.
PSEye is a data tracker, not a financial advisor, so it can't tell you whether to invest in EURO or any other stock. The price, valuation, dividend and disclosure data on this page is meant to help you do your own research. Consider your own goals, risk tolerance and time horizon, and consult a licensed financial advisor before making an investment decision. If you're weighing a fixed, regular investment instead of a single lump sum, PSEye's DCA calculator shows how that strategy would have performed historically.
To buy EURO shares, open an account with a PSE-accredited stockbroker (most Philippine banks and several standalone brokers offer online trading accounts), fund it, and place a buy order using the ticker symbol EURO. A completed trade typically settles two trading days later (T+2). PSEye doesn't process trades or recommend a specific broker.
Delayed/EOD data, not real-time. Figures are statistics on past closing prices, not a forecast.